Clinical Trials - July 12, 2021
Cantargia broadens the development of nadunolimab
Cantargia has announced that the development of nadunolimab (CAN04) has been broadened following the submission of an application of a phase I/II clinical trial to evaluate combination with chemotherapy in three different forms of solid tumors. Thus, the development of CAN04 is expanded to biliary tract cancer (BTC) and colorectal cancer (CRC), and extended to […]
Clinical Trials - May 25, 2021
Cantargia announces positive trial results
The company has reported positive results from the ongoing CANFOUR trial investigating nadunolimab (CAN04) in combination with gemcitabine/nab-paclitaxel (Abraxane) for first line treatment of patients with advanced pancreatic cancer (PDAC). The efficacy analysis included 33 patients. Overall, the efficacy compares favorably to historical control data. Median iPFS was 7.8 months and other notable findings include […]
Biotech Business - December 16, 2020
Cantargia has completed a directed share issue of approximately SEK 564 million
Investors in the Directed Share Issue are a wide range of Swedish and international investors, including AFA Försäkring, Swedbank Robur, Invus Public Equities LP, Point72 Asset Management, Handelsbanken Fonder and Granite Point Capital. The net proceeds from the Directed Share Issue are intended to be used to advance the company’s lead drug candidate, CAN04, which […]
Agreement - December 11, 2020
BioInvent and Cantargia sign manufacturing agreement
Cantargia and BioInvent International have announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. CAN10 is fully humanized monoclonal antibody targeting IL1RAP. CAN10 has been designed to block the signalling of the inflammatory cytokines IL-1, IL-33 and IL-36 resulting in unique […]
Clinical Trials - September 24, 2020
Cantargia reports new trial results and presents next development steps
Cantargia has announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). Tumor burden decreased in all 9 evaluable patients and in 6 of these patients, the decrease is large enough to be defined as a […]
Pharma Business - May 4, 2020
Cantargia’s IND application for CAN04 approved by FDA
Cantargia has announced that its IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development. CAN04 development can now be expanded […]
